Reduction of dyskinesias and psychiatric disability with clozapine over different time courses
Norman C. Moore, Peter A. LeWitt, Samuel Gershon
Abstract
Norman C. Moore, Peter A. LeWitt, Samuel Gershon
Abstract
Nine subjects with schizophrenia or schizoaffective disorder were treated with clozapine, 500 mg/day for at least 3 months. Each was affected by tardive dyskinesia whose severity was reduced significantly after 3 months of treatment but not at earlier monthly assessments. In contrast, psychiatric symptoms were lessened significantly after 1 month. The more delayed improvement of dyskinesia as compared to the pace of psychiatric improvement suggests a differential effect of the drug.
OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Nine subjects with schizophrenia or schizoaffective disorder were treated with clozapine, 500 mg/day for at least 3 months. Each was affected by tardive dyskinesia whose severity was reduced significantly after 3 months of treatment but not at earlier monthly assessments. In contrast, psychiatric symptoms were lessened significantly after 1 month. The more delayed improvement of dyskinesia as compared to the pace of psychiatric improvement suggests a differential effect of the drug.
Key concepts: Tardive dyskinesia, Clozapine, Schizoaffective disorder, Schizophrenia (object-oriented programming), Dyskinesia, Psychiatry, Medicine, Psychosis